Search research articles
Contact Us
Filters
Showing results (81-90 of 118) with videos related to
Page
of 12
Sort By:
Scientific Reports
|
May 24, 2020
The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes
Nicole E James, Jenna B Emerson, Ashley D Borgstadt, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
April 27, 2021
HE4 Overexpression by Ovarian Cancer Promotes a Suppressive Tumor Immune Microenvironment and Enhanced Tumor and Macrophage PD-L1 Expression
Rachael B Rowswell-Turner, Rakesh K Singh, Anze Urh, et al.
Gynecologic Oncology
|
June 11, 2022
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab
Melissa M Hardesty, Thomas C Krivak, Gail S Wright, et al.
Gynecologic Oncology
|
September 6, 2015
Associations between etiologic factors and mortality after endometrial cancer diagnosis: the NRG Oncology/Gynecologic Oncology Group 210 trial
Ashley S Felix, D Scott McMeekin, David Mutch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 2, 2022
Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
Jung-Min Lee, Richard G Moore, Sharad Ghamande, et al.
Journal of Medicinal Chemistry
|
October 22, 2025
Mechanism of Inhibition of the MeTC7 Ligand That Covalently Binds to VDR To Reduce PD-L1 Expression
Jérôme Castel, Carole Peluso-Iltis, Angelique Sanchez Dafun, et al.
Biorxiv : the Preprint Server for Biology
|
November 19, 2025
PSP-0119: Targeted IRAK4 Degradation as a Novel Therapeutic Strategy for FLT3-Mutant AML
Negar Khazan, Cameron Wa Snyder, Chandhana Ravi, et al.
Cancers
|
November 11, 2022
A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix<sup>®</sup> PC1 System
Evan N Cohen, Gitanjali Jayachandran, Richard G Moore, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 1, 2023
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
Future Oncology (London, England)
|
March 19, 2024
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 118) with videos related to
Sort By:
Page
of 12
Scientific Reports
|
May 24, 2020
The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes
Nicole E James, Jenna B Emerson, Ashley D Borgstadt, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
April 27, 2021
HE4 Overexpression by Ovarian Cancer Promotes a Suppressive Tumor Immune Microenvironment and Enhanced Tumor and Macrophage PD-L1 Expression
Rachael B Rowswell-Turner, Rakesh K Singh, Anze Urh, et al.
Gynecologic Oncology
|
June 11, 2022
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab
Melissa M Hardesty, Thomas C Krivak, Gail S Wright, et al.
Gynecologic Oncology
|
September 6, 2015
Associations between etiologic factors and mortality after endometrial cancer diagnosis: the NRG Oncology/Gynecologic Oncology Group 210 trial
Ashley S Felix, D Scott McMeekin, David Mutch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 2, 2022
Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
Jung-Min Lee, Richard G Moore, Sharad Ghamande, et al.
Journal of Medicinal Chemistry
|
October 22, 2025
Mechanism of Inhibition of the MeTC7 Ligand That Covalently Binds to VDR To Reduce PD-L1 Expression
Jérôme Castel, Carole Peluso-Iltis, Angelique Sanchez Dafun, et al.
Biorxiv : the Preprint Server for Biology
|
November 19, 2025
PSP-0119: Targeted IRAK4 Degradation as a Novel Therapeutic Strategy for FLT3-Mutant AML
Negar Khazan, Cameron Wa Snyder, Chandhana Ravi, et al.
Cancers
|
November 11, 2022
A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix<sup>®</sup> PC1 System
Evan N Cohen, Gitanjali Jayachandran, Richard G Moore, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 1, 2023
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
Future Oncology (London, England)
|
March 19, 2024
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
Page
of 12